← All trials
NCT05019846
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 30, 2021
- Primary completion
- Dec 1, 2024
- Completion date
- Dec 1, 2029
- First posted
- Aug 25, 2021
- Last posted
- Nov 2, 2021
- Enrollment
- 310
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di BresciaLead sponsor
- University of BresciaOverall official - principal investigator
- Spedali Civili di BresciaSponsor investigator
- Spedali Civili di BresciaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.